Show simple item record

dc.contributor.authorBiegstraaten, M
dc.contributor.authorWesnes, KA
dc.contributor.authorLuzy, C
dc.contributor.authorPetakov, M
dc.contributor.authorMrsic, M
dc.contributor.authorNiederau, C
dc.contributor.authorGiraldo, P
dc.contributor.authorHughes, D
dc.contributor.authorMehta, A
dc.contributor.authorMengel, K-E
dc.contributor.authorHollak, CEM
dc.contributor.authorMaródi, L
dc.contributor.authorvan Schaik, IN
dc.date.accessioned2018-02-26T10:31:54Z
dc.date.issued2012-11
dc.description.abstractBACKGROUND: The absence of neurological symptoms and signs is traditionally considered mandatory for a diagnosis of type 1 Gaucher disease (GD1), but in recent years many reports have emerged on neurological manifestations in GD1 patients. Nevertheless, it has been unclear whether cognitive deficits are part of the disease as well. METHODS: Cognitive function was assessed in a large cohort of GD1 patients with the use of the CDR system, a set of computerised cognitive tests. Testing was performed at baseline and every 6 months thereafter during a two-year study period. RESULTS: Our patient cohort (84 patients, median age 40 years, median time from diagnosis 15 years) showed mild deficits relative to healthy age-matched subjects on the composite scores: power of attention (Z-score (mean ± SD) -0.9 ± 1.37) and speed of memory (Z-score (mean ± SD) -1.39 ± 1.49). No decline in cognitive function was seen during the two-year period. Age correlated with the composite scores variability of attention and quality of working memory. Moreover, severely affected patients (Zimran severity score (SSI) ≥ 15) scored more poorly compared to mildly affected patients (SSI ≤ 5) on the composite measure power of attention, reflecting the ability to concentrate. CONCLUSIONS: GD1 patients exhibit mild deficits in power of attention and speed of memory, reflecting a decreased ability to focus attention and process information, together with a slowing in the speed of retrieval of items from memory. The clinical relevance of these findings is uncertain.en_GB
dc.description.sponsorshipThis work was supported by Actelion Pharmaceuticals Ltd, Allschwil, Switzerland. This study was set up under the auspices of the European Working Group on Gaucher Disease (EWGGD). MB received financial support from Actelion to conduct her activities related to this study. MB, CEMH, INvS and AM have received consultancy fees from Actelion for participation in clinical trial programs and other projects, and CEMH, INvS and AM have received speaker fees for participation in scientific congresses and sponsored events. MB and CEMH donate all fees to the Gaucher Stichting, a national foundation that supports research in the field of lysosomal storage disorders. Consulting fees for INvS are donated to the Stichting Klinische Neurologie, a local foundation that supports research in the field of neurological disorders. DH has received consultancy fees from Actelion for participation in clinical trials, grants for local laboratory projects, and speaker fees for participation in scientific congresses and sponsored events. KEM, PG and LM have received speaker fees from Actelion for participation in sponsored events. PG received consultancy fees for participation in local clinical projects. LM received a travel grant from Actelion and was financially supported by TÁMOP 4.2.1./B-09/1/KONV-2010-0007 and TÁMOP 4.2.2-08/1-2008-0015. CN got speaker fees for participation in scientific meetings. KAW was sole shareholder of Cognitive Drug Research Ltd. Cognitive Drug Research Ltd supplied the CDR System for the study and received financial support from Actelion. KAW is currently an employee of United BioSource Corporation (UBC) that owns the CDR System since August 2009. CL is an employee of Actelion Pharmaceuticals Ltd. MP and MM report no conflicts of interest.en_GB
dc.identifier.citationVol. 35, pp. 1093 - 1099en_GB
dc.identifier.doi10.1007/s10545-012-9460-7
dc.identifier.urihttp://hdl.handle.net/10871/31687
dc.language.isoenen_GB
dc.publisherSpringer Verlag (Germany)en_GB
dc.relation.urlhttps://www.ncbi.nlm.nih.gov/pubmed/22350617en_GB
dc.rights© The Author(s) 2012. This article is published with open access at Springerlink.com. s This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction in any medium, provided the original author(s) and the source are credited.en_GB
dc.subjectAdolescenten_GB
dc.subjectAdulten_GB
dc.subjectAgeden_GB
dc.subjectAttentionen_GB
dc.subjectCase-Control Studiesen_GB
dc.subjectCognitionen_GB
dc.subjectCognition Disordersen_GB
dc.subjectCohort Studiesen_GB
dc.subjectEuropeen_GB
dc.subjectFemaleen_GB
dc.subjectGaucher Diseaseen_GB
dc.subjectHumansen_GB
dc.subjectLongitudinal Studiesen_GB
dc.subjectMaleen_GB
dc.subjectMemoryen_GB
dc.subjectMemory, Short-Termen_GB
dc.subjectMiddle Ageden_GB
dc.subjectNeuropsychological Testsen_GB
dc.subjectProspective Studiesen_GB
dc.subjectYoung Adulten_GB
dc.titleThe cognitive profile of type 1 Gaucher disease patientsen_GB
dc.typeArticleen_GB
dc.date.available2018-02-26T10:31:54Z
dc.identifier.issn0141-8955
exeter.place-of-publicationNetherlandsen_GB
dc.descriptionThis is the final version of the article. Available from the publisher via the DOI in this record.en_GB
dc.identifier.journalJournal of Inherited Metabolic Diseaseen_GB


Files in this item

This item appears in the following Collection(s)

Show simple item record